European Biotech Acquisition Corp. Units
EBACU
EBACU was delisted on the 2nd of March, 2023.
61 hedge funds and large institutions have $89.3M invested in European Biotech Acquisition Corp. Units in 2021 Q1 according to their latest regulatory filings, with 61 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.69M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.25M |
| 3 |
LA
Linden Advisors
New York
|
+$4.98M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$4.1M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$3.78M |
Top Sellers
EBACU Hedge Fund Activity: Q1 2021 in Review
61 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Units (EBACU) for Q1 2021, worth a combined $89.3M.
Buyers outnumbered sellers: 61 funds opened new EBACU positions and 0 closed out — a net gain of 61 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $8.69M.
- 61 institutional investors held European Biotech Acquisition Corp. Units (EBACU) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $89.3M of European Biotech Acquisition Corp. Units stock for Q1 2021.
- 61 funds opened new European Biotech Acquisition Corp. Units positions in Q1 2021 and 0 closed out, a net change of +61 holders.
- The largest European Biotech Acquisition Corp. Units buyer in Q1 2021 was Millennium Management, an estimated $8.69M added.
Based on aggregated 13F filings for Q1 2021.